Switch theme
Sign up to access all valuation multiples
Sofwave Medical Ltd is engaged in the development, marketing, and production of non-invasive technology for skin rejuvenation and firming treatment.
n/a
Last FY Revenue $17.0M
Last FY EBITDA -$0.6M
$190M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Sofwave Medical achieved revenue of $17.0M and an EBITDA of -$0.6M.
Sofwave Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sofwave Medical valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $17.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $12.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 76% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -4% | XXX | XXX | XXX |
| EBIT | XXX | -$1.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | -6% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.3M | XXX | XXX | XXX |
| Net Margin | XXX | -8% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sofwave Medical's stock price is ILS 21 (or $6).
Sofwave Medical has current market cap of ILS 730M (or $208M), and EV of ILS 665M (or $190M).
See Sofwave Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $190M | $208M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sofwave Medical has market cap of $208M and EV of $190M.
Sofwave Medical's trades at 11.1x EV/Revenue multiple, and -303.3x EV/EBITDA.
Equity research analysts estimate Sofwave Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sofwave Medical's P/E ratio is not available.
See valuation multiples for Sofwave Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $208M | XXX | $208M | XXX | XXX | XXX |
| EV (current) | $190M | XXX | $190M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 11.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -303.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -185.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -160.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -248.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSofwave Medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Sofwave Medical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sofwave Medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sofwave Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -4% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sofwave Medical acquired XXX companies to date.
Last acquisition by Sofwave Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Sofwave Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Sofwave Medical headquartered? | Sofwave Medical is headquartered in Israel. |
| Is Sofwave Medical publicy listed? | Yes, Sofwave Medical is a public company listed on TAE. |
| What is the stock symbol of Sofwave Medical? | Sofwave Medical trades under SOFW ticker. |
| When did Sofwave Medical go public? | Sofwave Medical went public in 2021. |
| Who are competitors of Sofwave Medical? | Similar companies to Sofwave Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Sofwave Medical? | Sofwave Medical's current market cap is $208M |
| Is Sofwave Medical profitable? | Yes, Sofwave Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
